Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. PTC Therapeutics's Goodwill for the quarter that ended in Mar. 2022 was $82.3 Mil. PTC Therapeutics's Total Assets for the quarter that ended in Mar. 2022 was $1,799.6 Mil.
Therefore, PTC Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Mar. 2022 was 0.05.
PTC Therapeutics Goodwill-to-Asset Historical Data
The historical data trend for PTC Therapeutics's Goodwill-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
PTC Therapeutics Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Goodwill-to-Asset
-
0.07
0.05
0.04
0.04
PTC Therapeutics Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Goodwill-to-Asset
0.04
0.04
0.04
0.04
0.05
Competitive Comparison
For the Biotechnology subindustry, PTC Therapeutics's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics Goodwill-to-Asset Distribution
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Goodwill-to-Asset distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Goodwill-to-Asset falls into.
PTC Therapeutics Goodwill-to-Asset Calculation
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.
It is calculated by dividing goodwill by total assets.
PTC Therapeutics's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
PTC Therapeutics Goodwill-to-Asset Related Terms
Thank you for viewing the detailed overview of PTC Therapeutics's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.11(0.27%) Volume: 957,080 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:PTCT has been successfully added to your 
